Certain leukocytes release serine proteases that sustain inflammatory processes and cause disease conditions, such as asthma and chronic obstructive pulmonary disease. We identified β-ketophosphonate 1 (JNJ-10311795; RWJ-355871) as a novel, potent dual inhibitor of neutrophil cathepsin G (K i = 38 nM) and mast cell chymase (K i = 2.3 nM). The X-ray crystal structures of 1 complexed with human cathepsin G (1.85 Å) and human chymase (1.90 Å) reveal the molecular basis of the dual inhibition. Ligand 1 occupies the S 1 and S 2 subsites of cathepsin G and chymase similarly, with the 2-naphthyl in S 1 , the 1-naphthyl in S 2 , and the phosphonate group in a complex network of hydrogen bonds. Surprisingly, however, the carboxamido-N-(naphthalene-2-carboxyl)piperidine group is found to bind in two distinct conformations. In cathepsin G this group occupies the hydrophobic S 3 /S 4 subsites, whereas in chymase it does not; rather, it folds onto the 1-naphthyl group of the inhibitor itself. Compound 1 exhibited noteworthy antiinflammatory activity in rats for glycogeninduced peritonitis and lipopolysaccharideinduced airway inflammation. In addition to a marked reduction in neutrophil influx, 1 reversed increases in inflammatory mediators interleukin-1α, interleukin-1β, tissue necrosis factor-α, and monocyte chemotactic protein-1 in the glycogen model and increases in airway nitric oxide levels in the lipopolysaccharide model. These findings demonstrate that it is possible to inhibit both cathepsin G and chymase with a single molecule, and suggest an exciting opportunity in the treatment of asthma and chronic obstructive pulmonary disease.
enzymes that are implicated in pathological inflammatory conditions. The adverse effects of Cat G and chymase go beyond the breakdown of matrix proteins. Cat G is linked with activated macrophages and chymase triggers generation of cytokines and chemokines, which stimulate the infiltration of inflammatory cells. Thus, Cat G and chymase contribute in a major way to selfpropagating, chronic inflammation.
Since Cat G and chymase have structurally homologous catalytic clefts, we envisioned an opportunity to inhibit both proteases with a single molecule. Through structure-based drug design, we have discovered a novel, nonpeptide, smallmolecule inhibitor of both Cat G and chymase, represented by structure 1 (Fig. 1) . We report the three-dimensional structures for the Cat G and chymase complexes of 1, which define the molecular interactions of 1 in the active site of each enzyme and reveal two different binding modes relative to occupancy of the hydrophobic S 3 /S 4 pocket. In addition, we have investigated the biological properties of this dual inhibitor and found that it has noteworthy anti-inflammatory activity in two animal models.
EXPERIMENTAL PROCEDURES
Compound 1─Compound 1 (JNJ-10311795; RWJ-355871) was synthesized in our laboratories according to published methodology (22) . Diethyl 1-naphthylmethylphosphonate was lithiated with butyllithium, and then reacted with 2,3-naphthoic anhydride. The product was treated with N-(1-naphthoyl-4-piperidinyl)-N'-methylamine in the presence of N,N'-dicyclohexylcarbodiimide, and then bromotrimethylsilane in pyridine. After addition of 1 N HCl, 1 (as a racemate) was converted to a tromethamine (Tris) salt, which was purified by recrystallization from 2-propanol. Compound 1 is stereochemically labile at the α-phosphonyl carbon atom. In a 600-MHz 1 H NMR study, deuterium exchange occurred at this stereocenter with a t 1/2 of 18.5 h at 37 °C (MeOHd 4 :D 2 O, 1:1; pD 6.7). Details for the synthesis and characterization of 1 can be found in Supporting Information, which is published in JBC On-line.
Enzymes─Human neutrophil Cat G from Athens Research and Technology, Inc. (Athens, GA) was used in the enzyme inhibition and crystallography studies. This enzyme is a single protein species with variable glycosylation, having a molecular weight of 23.5 kDa. The material was supplied as a salt-free lyophilized solid (≥95% purity by SDS-PAGE). Human skin chymase from Cortex Biochem, Inc. (San Leandro, CA) was used in the enzyme inhibition studies. The material was supplied as a liquid in 50 mM sodium acetate buffer (pH 5.0) with 1 M sodium chloride (>95% purity by SDS-PAGE and gel diffusion). The purified human chymase used in our crystallography studies was obtained from Prof. Norman M. Schechter (University of Pennsylvania) (23) . This recombinant enzyme is a single protein species with two sugar-bearing glycosylation sites, having a molecular weight of 24.3 kDa. The material was supplied as a lyophilized solid (>95% purity by SDS-PAGE).
Enzyme Inhibition Assays─Enzyme-catalyzed hydrolysis rates were measured for human neutrophil Cat G (Athens) or human skin chymase (Cortex Biochem) spectrophotometrically by using the chromogenic substrate Suc-Ala-Ala-Pro-Phe-(p-nitroanilide) (Bachem Bioscience Inc., King of Prussia, PA; K m Cat G = 3.0 ± 0.6 mM, K m chymase = 0.33 ± 0.09 mM) in aqueous buffer (Cat G: 100 mM Hepes, 500 mM NaCl, pH 7.4; chymase: 450 mM Tris, 1800 mM NaCl, pH 8.0), with a microplate reader (Molecular Devices Corp., Sunnyvale, CA). Changes in absorbance at 405 nM were monitored just after addition of enzyme, with and without inhibitor present. Inhibition constants (K i values) were determined under conditions for analysis of Michaelis-Menten kinetics (37 °C, monitored for 15 min; Cat G: 70 nM enzyme, 0.3-10 mM substrate; chymase: 10 nM enzyme, 0.1-3.0 mM substrate) (24) . The K i values were obtained by using the program K-Cat (BioMetallics, Inc., Princeton, NJ).
Crystallization─Human Cat G (Athens) and human chymase (Prof. N. Schechter) were used in the crystallization studies without further purification.
We screened for crystallization conditions with Hampton Screen Kits I and II (Hampton Research, Aliso Viejo, CA), and grew diffraction quality crystals by the sitting-drop method at 23 °C over 7 days. For 1•Cat G, the protein and inhibitor were mixed in a 1:2 molar ratio and the crystals were grown from 20% PEG4K, 0.2 M lithium sulfate, 20 mM zinc sulfate, and 0.1 M Tris (pH 8.5). For 1•chymase, the protein and inhibitor were mixed in a 1:4 molar ratio and the crystals were grown from 1.8 M ammonium sulfate, 0.1 M 4-morpholineethanesulfonic acid (MES; pH 6.5), and 0.01 M cobalt chloride.
Both crystal forms are orthorhombic and contain one molecule of complex in the asymmetric unit. The unit cell parameters and space group symmetry are presented in Table I .
X-ray Data Collection─The X-ray diffraction data were collected on an ADSC Quantum-4 CCD detector by using monochromatic radiation (λ = 0.9 Å) at the BIOCARS Beamline 14-BM-C of the Advanced Photon Source (Argonne National Laboratories). For 1•Cat G, the crystal was flashfrozen in a newly prepared mother liquor by adding 18% glycerol as a cryoprotectant. For 1•chymase, crystals were flash-frozen after cryoprotection in Paratone oil (Hampton Research) for 30 min. The X-ray data for the two complexes were recorded to resolutions of 1.85 and 1.90 Å, respectively (Table I ). Processing and scaling was performed with HKL-2000 (25) .
X-ray Structural Determination and Refinement─The crystal structures of both complexes were solved by molecular replacement. For 1•Cat G, the program CNS (26) was used to solve the structure, with data in the range of 15-4 Å resolution and the structure of human Cat G (27) as the search model. The structure of 1•chymase was solved by using MOLREP, a part of the CCP4 program package (28) , employing all data to 3.0 Å resolution and the structure of human chymase (23) as the search molecule. The structures were refined by using CNS (26) . All reflections greater than zero (|F|/σ|F| > 0) were retained and 5% of the reflections from each data set were randomly selected as a test set for the calculation of R free (29) . After initial rigid-body refinement, each structure was subjected to molecular dynamics refinement by simulated annealing (30) .
After refinement of atomic positions and individual isotropic thermal factors, including a bulk solvent correction, water molecules and inhibitor 1 were introduced. Model building based on the electron-density difference maps was conducted manually with the program Turbo-Frodo (31) on a Silicon Graphics Indigo II workstation. The stereochemical quality of the structures was checked by using the program PROCHECK (32) . Refinement data and model parameters are listed in Table I .
Model Generation and Fitting of 1─A model for inhibitor 1 was generated by using the Builder module of Insight II (Accelrys, San Diego, CA). Proper electrostatic potentials were assigned to all of the atoms of the molecule. The energy of the molecule was minimized by using the conjugate gradient algorithm in the Discover module of Insight II. Minimized 1 was then fitted to the difference electron density of the 1•chymase crystal, first, then of the 1•Cat G crystal, with torsional rotations and the breaking and making bonds when necessary. The Discover module was used again to minimize the energy of the molecule in the new conformations. These steps were repeated several times until the molecule fit well into the electron-density maps.
Glycogen-Induced Peritonitis in Rats (33, 34) ─A glycogen solution (25 mL, 1% w/v; Sigma, St. Louis, MO) was injected intraperitoneally (i.p.) into male Sprague-Dawley rats. Ascites fluid was collected from the peritoneum 4 h later. Aliquots were centrifuged (Beckman GS-6, 6000 rpm, 10 min, 23 °C), and supernatants were collected and frozen for analysis. The cytokines interleukin-1α (IL-1α), IL-1β, and tissue necrosis factor-α (TNF-α), and the chemokine monocyte chemotactic protein-1 (MCP-1), were measured with ELISA kits (BioSource International, Camarillo, CA). The cell pellet was resuspended in saline for quantification of neutrophils with an automated cell counter (Bayer Advia 120 Hematology System). Compound 1 was dosed intravenously (i.v.) to four groups of rats (N = 6/group) at 30 min prior to glycogen as a bolus of 0.1, 0.25, 0.55, or 0.5 mg/kg (in saline) followed by an infusion of 0.2, 0.5, 2.1, or 10 mg/kg/h, respectively, which resulted in composite doses of 1, 2.5, 10, and 45.5 mg/kg, respectively, over the course of the experiment (4.5 h). In a control group, an equivalent volume of saline (vehicle) was infused i.v. into glycogen-treated rats (N = 18). In another group of rats (N = 12), the positive control dexamethasone (DEX; Sigma) was dosed intramuscularly (i.m.) at 1 mg/kg, 30 min prior to glycogen. Four hours after the administration of glycogen, the ascites fluid was drained from the peritoneum and the samples were centrifuged; the cell pellet was resuspended in saline and the neutrophils were quantified as stated above. (30) ─We exposed two groups of Sprague-Dawley rats to aerosolized saline (N = 24) or to an aerosolized solution of 1 (ca. 1 mg/kg; N = 17), followed 30 min later by intratracheal instillation of 100 µg of LPS (E. coli 0111:B4; Sigma). A third group of rats received inhaled saline as a baseline control (N = 5). At 24 h following LPS, the rats were euthanized and their airways were immediately lavaged with 10 mL of heparinized saline. The broncho-alveolar lavage (BAL) samples were centrifuged (Beckman GS-6, 1530 rpm, 10 min, 23 °C) to obtain a cell pellet, which was resuspended in 1 mL of 10% fetal bovine serum (Cellgro/Media Tech, Inc., Herndon, VA) and recentrifuged (2000 rpm) through 1 mL of Lympholyte (Cedarlane Laboratories, Hornby, Ontario, Canada). Cells retained at the interface were collected, resuspended in 2% serum (2 mL), and centrifuged (1530 rpm). The cell pellet was resuspended in 2% serum (1 mL) and cell numbers were determined by using an automated counter (Bayer Advia 120). A separate study assessed the effects on nitric oxide levels under the LPS protocol. Expired gases were collected from conscious rats, one at a time, in a sealed chamber by constant, flow-through air sampling (with ambient NO being removed from the inlet air by passage through aqueous potassium permanganate and an activated carbon filter). The NO levels in the expired gases from the outlet were measured by a gas-phase chemiluminescent reaction between NO and ozone (Sievers Nitric Oxide Analyzer NOA 280i, Ionics Instruments, Boulder, CO). The amount of NO in the LPS model was measured in the presence and absence of 
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RESULTS
Dual Inhibition of Cat G and Chymase─At the outset of our studies, we performed highthroughput screening of the Johnson & Johnson proprietary compound library for inhibition of Cat G and identified prototype 2 ( Fig. 1) as a moderately potent inhibitor (IC 50 = 4.1 µM). An X-ray structure of 2•Cat G (3.0 Å) was used to guide structural modifications for optimizing potency (22) . Thus, we designed, synthesized, and evaluated derivatives with functional groups that could project into the S 3 and S 4 subsites of Cat G, an inviting hydrophobic region not utilized by 2. This effort eventually led us to β-ketophosphonate 1, which exhibits potent inhibition of Cat G (K i = 38 ± 8 nM, N = 7; IC 50 = 82 ± 10 nM, N = 59). This compound showed standard MichaelisMenten kinetics as a reversible, competitive inhibitor with a rapid on-rate (k on = 4.8 ± 2.9 x 10 5 M -1 s -1 , N = 4) and a moderately slow off-rate (k off = 3.7 ± 0.5 x 10 -2 s -1 , N = 4). In profiling 1 for enzyme selectivity, we discovered that it also inhibits chymase, a serine protease that is homologous to Cat G, with exceptional potency (K i = 2.3 ± 0.5 nM, N = 9; IC 50 = 4.5 ± 0.7 nM, N = 37). We observed Michaelis-Menten kinetics (reversible, competitive chymase inhibition) with a rapid on-rate (k on = 1.4 ± 0.5 x 10 5 M -1 s -1 , N = 5) and a moderately slow off-rate (k off = 5.5 ± 3.0 x 10 -2 s -1 , N = 5). Compound 1 was found to possess excellent selectivity vs. several other serine proteases: <50% inhibition at 100 µM for factor Xa, factor IXa, plasma kallikrein, urokinase plasminogen activator, tryptase, proteinase 3, and leukocyte elastase; K i = 5.6 µM for thrombin; K i = 11 µM for plasmin; K i = 15 µM for trypsin; IC 50 = 25 µM for tissue plasminogen activator. There was moderate inhibition of chymotrypsin (K i = 490 ± 90 nM, N = 9).
Structures of the Two Complexes─Suitable cocrystals of complexes of 1 (racemate) with human Cat G and chymase were obtained, and the structure of each was determined to resolutions of 1.85 and 1.90 Å, respectively (Table I) . Complex 1•Cat G consists of 224 amino acid residues, 1 inhibitor molecule, 261 solvent molecules, and 5 sulfate anions. All of the residues from Ile-16 to Ser-244 were located in strong electron density except for residues Thr-36a to Pro-38, which form a surface loop (assigned zero occupancy). Complex 1•chymase crystal contains one protein molecule of 226 residues, one inhibitor molecule, one cobalt cation, 8 sulfate anions, one molecule modeled as a MES anion, and three molecules modeled as N-linked N-acetylglucosamine. All of the residues from Ile-16 to Thr-245 were located in strong electron density. Electron-density maps for 1 in each complex are depicted in Fig. S1 , contained in the Supporting Information published in JBC On-line. Atomic coordinates for the two structures were deposited in the Protein Data Bank: 1•CatG, 1T32; 1•chymase, 1T31.
Molecular Interactions of 1─Our results from the crystallography provide insight into the molecular basis of the potent enzyme inhibition of 1, by defining the molecular interactions in the enzyme active sites (Fig. 2) . In both complexes, the active site is occupied by the R enantiomer of 1. For 1•Cat G ( Fig. 2A and C) , many of the key interactions of the ligand within S 1 , S 2 , and the catalytic site are similar to those observed earlier for 2•Cat G (22). The 2-naphthyl group occupies S 1 and the 1-naphthyl group occupies S 2 , the latter being involved in an aromatic-stacking interaction with the imidazole of His-57. One phosphonate oxygen is hydrogen-bonded with Nε of His-57 and Oγ of Ser-195, another oxygen is H-bonded to Nε of Lys-192, and a third is H-bonded to the NH of Gly-193 and Ser-195 Oγ, in the "oxyanion hole" (Fig. 2C) . The unenolized ketone oxygen is Hbonded to Nε of Lys-192.
In our structure-based drug design effort, we anticipated that the carboxamido-N-(naphthalene-2-carboxyl)piperidine segment of 1 would occupy the hydrophobic S 3 /S 4 cavity, the surface of which is defined by the side chains of Tyr-215, Ile-99, and Phe-172. In fact, this binding mode, with the piperidine ring (chair conformation) orienting the third naphthyl in the S 3 /S 4 pocket, was observed. Thus, the enhanced potency of 1 (IC 50 = 82 nm) over 2 (IC 50 = 4100 nM) can be largely attributed to these additional hydrophobic interactions (22) .
Because of the close sequence homology (>50%) between Cat G and chymase, and the homologous structure of their active sites (ca. 80%), we supposed that the binding mode for 1•chymase would be similar to that for 1•Cat G. Indeed, 1 occupies the S 1 and S 2 domains of chymase ( Fig. 2B and D) in a virtually identical manner to 1•Cat G, although there are small differences in the hydrogen-bonding network between the two complexes. In 1•chymase, one oxygen of the phosphonate is H-bonded to Lys-192 Nε and Lys-40 Nε, while another is H-bonded to His-57 Nε, Lys-40 Nε, and Ser-195 Oγ (Fig.  2D) . As seen for 1•Cat G (above), a third oxygen atom occupies the oxyanion hole, forming hydrogen bonds with the NH of Gly-193 and Ser-195 Oγ. The unenolized ketone oxygen is Hbonded to Lys-192 Nε. However, there is a striking difference between the two complexes relative to the S 3 /S 4 region. Even though this region of chymase, defined by the side chains of Tyr-215, Leu-99, and Phe-173, is hydrophobic, in analogy with Cat G, 1 adopts an unusual folded conformation with the naphthalene-2-carboxyl unit juxtaposed to the 1-naphthyl ring (Fig. 2D) . The distance of closest approach of 3.7 Å between the two naphthalene rings supports an aromaticstacking interaction. Basically, in this case the ligand does not reside within the S 3 /S 4 binding pocket at all.
Inhibition of Acute Peritonitis in Rats─With dual inhibitor 1 in hand, we investigated its pharmacological properties in rat models of inflammation. We tested 1 in an experimental model of acute peritonitis in rats (4.5-h protocol) (33, 34) . Injection of a glycogen solution (i.p.) caused a large influx of neutrophils into the peritoneal cavity. Cell counts in the peritoneal lavage at 4 h after glycogen administration was used as an index of inflammation (Fig. 3) . The anti-inflammatory steroid DEX (1 mg/kg, i.m., 30 min prior to glycogen) inhibited neutrophil influx by 75% at 4 h post-glycogen (positive control). Administration of 1 (i.v. bolus dose, 30 min prior to glycogen; i.v. infusion over 4.5 h for steadystate plasma levels) prevented the accumulation of neutrophils in the peritoneum in a dose-dependent manner, with a maximal inhibition of 70% (total dose = 45.5 mg/kg). Separately, we measured myeloperoxidase (MPO) levels, a quantitative biomarker of neutrophils during an inflammatory response (36, 37) , in the ascites fluid 4 h after glycogen administration. The average increase in MPO activity was 7.5 mU/µL, which is high relative to the undetectable levels in saline controls. Treatment with 1 as a bolus (0.5 mg/kg, i.v.) 30 min prior to glycogen, followed by a 10-mg/kg/h i.v. infusion for 4.5 h (total dose = 45.5 mg/kg), reduced the increase in MPO by 50% (with a 50% reduction in neutrophil counts).
Since cytokines and chemokines contribute to the neutrophilia in glycogen-induced peritonitis (38) , the levels of IL-1α, IL-1β, TNF-α, and MCPAdministration of 1 (0.5-mg/kg i.v. bolus, 30 min prior to glycogen; 10-mg/kg/h infusion over 4.5 h; total dose = 45.5 mg/kg) sharply reduced the increases in IL-1α, IL-1β, and MCP-1, albeit not the increase in TNF-α (Fig. 4A-D) . Plasma levels of TNF-α and MCP-1 were elevated by glycogen treatment (Fig. 4E and F) , but plasma levels of IL-1α and IL-1β were not (data not shown). Dosing with 1 under the same regime caused a 50% reduction in the glycogen-induced increases of TNF-α and MCP-1 in plasma (Fig. 4E and F) .
Inhibition of Acute Airway Inflammation in Rats─Neutrophils are a major source of the protease burden that promotes lung damage in COPD (12, 39) . By way of an acute experimental model, LPS can be administered by inhalation to develop an inflammatory condition in the airways and lungs, characterized by excessive neutrophil influx (35) . Rats were treated with aerosolized saline or 1, followed by the administration of LPS 30 min later, and the levels of inflammatory cells in the BAL were determined after 24 h (Fig. 5) . Compared to baseline cell levels in the BAL for saline-treated controls, LPS caused a large increase in total white blood cell counts in the BAL, especially for neutrophils and lymphocytes. Compound 1 reversed these LPS-induced effects, as well as the increases in monocytes, eosinophils, and basophils. Instillation of LPS into the lungs of rats also caused a sharp increase in exhaled NO, an indirect determinant of airway inflammation, from 3-5 ppb (baseline level) to 12-20 ppb. Aerosol administration of 1 at ca. 1 or 3 mg/kg, 30 min prior to LPS, reduced the elevated levels of exhaled NO by 20% or 37%, respectively.
DISCUSSION
We have identified 1 as a novel, potent dual inhibitor of human neutrophil Cat G and human mast cell chymase. These powerful inflammatory proteases are thought to contribute significantly to the conditions of asthma and COPD in humans, especially when their endogenous inhibitors are depleted.
Given the potential therapeutic importance of 1, we successfully determined the crystal structures for each complex, 1•Cat G and 1•chymase, at 1.85 Å and 1.90 Å resolution. Ligand 1 occupies the S 1 and S 2 subsites of Cat G and chymase in a similar manner, with the 2-naphthyl in S 1 , the 1-naphthyl in S 2 , the ketone oxygen H-bonded to Lys-192 Nε, and the phosphonate group in a complex network of hydrogen bonds. One of the phosphonate oxygen atoms satisfies the "oxyanion hole", with hydrogen bonds to Gly-193 NH and Ser-195 Oγ. However, there was a dramatic difference between the complexes relative to the carboxamido-N-(naphthalene-2-carboxyl)piperidine group. In Cat G this group occupies the hydrophobic S 3 /S 4 region, and is probably responsible for the high Cat G potency of 1 (IC 50 = 82 nM) in comparison to 2 (IC 50 = 4100 nM) (22) . However, in chymase this group does not reside within the S 3 /S 4 region at all; rather, it folds back onto the ligand itself in an apparent hydrophobic-collapse model (40, 41). This structural difference entails conformational changes in 1 mainly associated with a rotation of ca. 180° about the C-N bond of the naphthalene-2-carboxyl subunit (Fig. 2D) . Surprisingly, despite this lack of occupancy in the S 3 /S 4 pocket of chymase, 1 is a very potent chymase inhibitor (IC 50 = 4.5 nM), substantially more potent than 2 (IC 50 = 400 nM; determined in our laboratory). Perhaps, enthalpic stabilization of 1 via the hydrophobic collapse inside the active site of chymase may be largely responsible for the higher potency of 1 relative to 2. In any event, it is noteworthy that 1 binds within the homologous active sites of these chymotrypsin-like enzymes in two different modes.
To understand this outcome further, one can compare the disposition of active-site residues of Cat G and chymase in our two structures. A noteworthy difference is that Gly-173 and Ile-171 in Cat G correspond with Arg-174 and His-172 in chymase. Although these residues are located at the far perimeter of S 4 in each enzyme, they may alter the hydrophobic-hydrophilic balance of the enzyme surface from more hydrophobic in Cat G to more hydrophilic in chymase. In this regard, the surface of the S 3 /S 4 region in chymase is comparatively less hydrophobic and thus possibly less favorable for binding the naphthalene-2-carboxyl group.
It is of interest to compare the active site residues in our two structures with those in the structures reported in the literature. The overall active-site topologies of 1•Cat G and SucValProPhe In examining the pharmacological properties of 1 in rat models of inflammation, we found that this dual inhibitor is capable of markedly reducing neutrophil influx into the sites of inflammation. Furthermore, 1 counteracted the increases in the key inflammatory mediators IL-1α, IL-1β, TNF-α, and MCP-1 in glycogen-induced peritonitis and the increases in airway nitric oxide levels in LPSinduced lung inflammation. Airway neutrophilia is a hallmark of COPD (43, 44), which is a major health problem worldwide in terms of mortality and morbidity (45). Since 1 substantially reduced neutrophil infiltration in the rat models of neutrophil-rich inflammation, this agent may be potentially useful for the treatment of COPD. In the glycogen model, 1 markedly blunted the increase in the pro-inflammatory cytokine TNF-α and effectively counteracted the rise in the chemokine MCP-1, both of which are elevated in COPD (44, 46). These findings suggest that 1 has potential for the treatment of asthma and COPD.
Additionally, Cat G and chymase can serve to convert angiotensin I to angiotensin II (47, 48). Since angiotensin II is a strong proliferative agent that contributes to tissue hypertrophy, fibrosis, and remodeling in chronic inflammatory diseases of the lungs (49), kidneys (50), and cardiovascular system (51), the long-term oral administration of a Cat G/chymase inhibitor could be therapeutically useful. In this respect, dual inhibitor 1 may be limited because of its low oral bioavailability (F < 1%, in rats) and relatively short plasma half-life (t 1/2 = 50 min, in rats). However, the aerosol administration of 1 could provide an effective means for treating chronic airway and pulmonary inflammation.
There has been considerable attention paid to inhibitors of neutrophil elastase, which contributes to airway inflammation (52). Although elastase is involved in lung destruction in α-1 antitrypsin deficiency, it may not be critically involved in COPD (53, 54). Thus far, the clinical utility of elastase inhibitors in COPD has not been proven, even though selective oral agents have been available for several years (52). Perhaps, the inflammatory proteases Cat G (12) and chymase (55) may play a more important role in the pathophysiology of COPD, by triggering an array of harmful factors, including matrix degradation, leukocyte recruitment, and tissue remodeling. Our results with 1 in two rat models of inflammation suggest that inhibition of more than one crucial inflammatory protease might afford effective pharmacotherapy. Disease conditions caused by airway inflammation, and associated with the aforementioned protease-antiprotease imbalance, such as COPD and asthma, could benefit from 1 or related dual agents. The therapeutic opportunities for this type of agent would gain better definition from further pharmacological studies, especially with other mammalian species.
From a mechanistic standpoint, additional work is also needed to understand the independent roles played by Cat G and chymase in vivo with respect to their inhibition, by means of selective inhibitors of Cat G and chymase. Our research with 1, and related molecular entities, is proceeding in this direction. d R free is the test reflection data set (29) . e Root-mean-squared deviation (Rmsd) from ideal bond lengths and angles and Rmsd in Bfactors of bonded atoms.
TABLES
f mm, main chain to main chain; ms, main chain to side chain, ss, side chain to side chain. g Calculated by using PROCHECK (32) . 
